Influence of Treatment with Alendronate on the Speed of Sound, an Ultrasound Parameter, of the Calcaneus in Postmenopausal Japanese Women with Osteoporosis: a Clinical Practice-based Observational Study

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2012 Jul 7

PMID 22767992

Citations 2

Authors

Jun Iwamoto

Tetsuya Takada

Yoshihiro Sato

Hideo Matsumoto

Affiliations

Soon will be listed here.

Abstract

Purpose: The influence of alendronate (ALN) treatment on the quantitative ultrasound parameters of the calcaneus remains to be established in Japanese patients. The aim of the present clinical practice-based observational study was to examine the influence of ALN treatment for 1 year on the speed of sound (SOS) of the calcaneus and bone turnover markers in postmenopausal Japanese women with osteoporosis.

Patients And Methods: Forty-five postmenopausal Japanese women with osteoporosis who had received treatment with ALN for more than 1 year were enrolled in the study. The SOS and bone turnover markers were monitored over 1 year of ALN treatment.

Results: The urinary levels of cross-linked N-terminal telopeptides of type I collagen and serum levels of alkaline phosphatase decreased significantly from the baseline values (-44.9% at 3 months and -22.2% at 12 months, respectively). The SOS increased modestly, but significantly, from the baseline value (0.6% at both 6 and 12 months). The percentage decrease in the urinary levels of cross-linked N-terminal telopeptides of type I collagen at 3 months was significantly correlated with the percentage increase in the SOS only at 6 months (correlation coefficient, 0.299).

Conclusion: The present study confirmed that ALN treatment suppressed bone turnover, producing a clinically significant increase in the SOS of the calcaneus in postmenopausal Japanese women with osteoporosis.

Citing Articles

Effect of risedronate on speed of sound in postmenopausal women with osteoporosis.

Iwamoto J, Takada T, Sato Y, Matsumoto H World J Orthop. 2013; 4(4):316-22.

PMID: 24147269 PMC: 3801253. DOI: 10.5312/wjo.v4.i4.316.

Treatment options for postmenopausal osteoporosis.

Walsh G Ther Clin Risk Manag. 2012; 8:367-8.

PMID: 22956875 PMC: 3431956. DOI: 10.2147/TCRM.S36280.

References

Gonnelli S, Cepollaro C, Montagnani A, Martini S, Gennari L, Mangeri M . Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. Osteoporos Int. 2002; 13(5):415-21. DOI: 10.1007/s001980200048. View

Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M . Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001; 19(6):331-7. DOI: 10.1007/s007740170001. View

Kaji H, Hisa I, Inoue Y, Naito J, Sugimoto T, Kasuga M . Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. J Bone Miner Metab. 2008; 27(1):76-82. DOI: 10.1007/s00774-008-0005-y. View

Iwamoto J, Takeda T, Sato Y, Uzawa M . Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol. 2004; 23(5):383-9. DOI: 10.1007/s10067-004-0881-z. View

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155. DOI: 10.1002/14651858.CD001155.pub2. View

Iwamoto J, Takeda T, Sato Y, Uzawa M . Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. J Bone Miner Metab. 2005; 23(3):238-42. DOI: 10.1007/s00774-004-0590-3. View

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K . Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab. 2004; 22(5):462-8. DOI: 10.1007/s00774-004-0508-0. View

Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M . Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab. 2005; 23(5):382-8. DOI: 10.1007/s00774-005-0616-5. View

10.

Iwamoto J, Miyata A, Sato Y, Takeda T, Matsumoto H . Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures. Ther Clin Risk Manag. 2009; 5:773-9. PMC: 2762435. DOI: 10.2147/tcrm.s6901. View

11.

Ikeda Y, Iki M . Precision control and seasonal variations in quantitative ultrasound measurement of the calcaneus. J Bone Miner Metab. 2004; 22(6):588-93. DOI: 10.1007/s00774-004-0527-x. View

12.

Wuster C, HEILMANN P, PEREIRA-LIMA J, Schlegel J, Anstatt K, Soballa T . Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities. Exp Clin Endocrinol Diabetes. 1998; 106(4):277-88. DOI: 10.1055/s-0029-1211986. View

13.

Pazianas M, Compston J, Huang C . Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010; 25(1):2-10. DOI: 10.1359/jbmr.091201. View

14.

Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041):1535-41. DOI: 10.1016/s0140-6736(96)07088-2. View

15.

Iwamoto J, Takeda T, Sato Y, Uzawa M . Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol. 2006; 26(2):161-7. DOI: 10.1007/s10067-006-0252-z. View

16.

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H . Seven years' experience with alendronate in postmenopausal Japanese women with osteoporosis. Ther Clin Risk Manag. 2010; 6:201-6. PMC: 2861441. DOI: 10.2147/tcrm.s10136. View

17.

Yamaguchi T, Yamamoto M, Kanazawa I, Yamauchi M, Yano S, Tanaka N . Quantitative ultrasound and vertebral fractures in patients with type 2 diabetes. J Bone Miner Metab. 2011; 29(5):626-32. DOI: 10.1007/s00774-011-0265-9. View

18.

Fujiwara S, Sone T, Yamazaki K, Yoshimura N, Nakatsuka K, Masunari N . Heel bone ultrasound predicts non-spine fracture in Japanese men and women. Osteoporos Int. 2005; 16(12):2107-12. DOI: 10.1007/s00198-005-2008-z. View

19.

Ito M, Nishida A, Kono J, Kono M, Uetani M, Hayashi K . Which bone densitometry and which skeletal site are clinically useful for monitoring bone mass?. Osteoporos Int. 2003; 14(12):959-64. DOI: 10.1007/s00198-003-1497-x. View

20.

Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T . A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int. 1999; 10(3):183-92. DOI: 10.1007/s001980050214. View